Last $6.75 USD
Change Today +0.10 / 1.50%
Volume 639.2K
PGNX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:48 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

progenics pharmaceuticals (PGNX) Snapshot

Open
$6.63
Previous Close
$6.65
Day High
$6.80
Day Low
$6.42
52 Week High
01/2/15 - $7.84
52 Week Low
05/9/14 - $3.10
Market Cap
470.9M
Average Volume 10 Days
743.8K
EPS TTM
$0.07
Shares Outstanding
69.6M
EX-Date
--
P/E TM
90.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for PROGENICS PHARMACEUTICALS (PGNX)

progenics pharmaceuticals (PGNX) Related Businessweek News

No Related Businessweek News Found

progenics pharmaceuticals (PGNX) Details

Progenics Pharmaceuticals, Inc. develops medicines for oncology. The company offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient; and for treatment of OIC inpatients with non-cancer pain. It also develops Relistor-oral that is in Phase III testing for the treatment of OIC. In addition, the company’s clinical-stage product candidates include prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has completed Phase II testing in chemotherapy-experienced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radiotherapeutic product candidate, which is in Phase IIb registrational trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma. Further, it develops MIP-1095, a PSMA-targeted small molecule radiopharmaceutical that is in clinical development stage for the treatment of prostate cancer. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide other than Japan; and collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York.

69 Employees
Last Reported Date: 03/13/14
Founded in 1986

progenics pharmaceuticals (PGNX) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $535.6K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $279.6K
Executive Vice President of Medical Affairs
Total Annual Compensation: $426.5K
Senior Vice President of Manufacturing
Total Annual Compensation: $296.5K
Compensation as of Fiscal Year 2013.

progenics pharmaceuticals (PGNX) Key Developments

Progenics Pharmaceuticals Presents Positive Phase 2 Data for PSMA

Progenics Pharmaceuticals, Inc. announced full results from its Phase 2 clinical study of PSMA ADC in patients with metastatic castration-resistant prostate cancer (mCRPC), including new data from the recently completed chemo-na ve cohort. The data was presented in a poster session and was also selected for inclusion in the ASCO GU Audio Poster Tour at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium, taking place from February 26 28, 2015 in Orlando, Florida. The Phase 2 trial assessed the anti-tumor activity and tolerability of PSMA ADC, an antibody drug conjugate, in both taxane-experienced and chemo-na ve patients that had progressed following treatment with abiraterone and/or enzalutamide. In the chemo-na ve cohort, treatment with PSMA ADC reduced tumor size and levels of PSA and CTCs (circulating tumor cells) evidencing strong anti-tumor activity. Among these chemo-na ve patients, one (3%) had a complete radiological response, four (14%) had a partial radiological response, 22 (76%) showed stable disease, and two (7%) experienced progressive disease. The study enrolled 119 patients with mCRPC that had progressed following treatment with abiraterone and/or enzalutamide, including 84 taxane-experienced patients and 35 chemo-na ve patients. Patients in the trial received PSMA ADC 2.5mg/kg or 2.3 mg/kg intravenously three times weekly for up to 8 cycles. Safety, antitumor activity, and exploratory biomarkers were assessed.

Progenics Pharmaceuticals, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 02:05 PM

Progenics Pharmaceuticals, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 02:05 PM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Mark R. Baker, Chief Executive Officer, Director and Member of Science & Strategy Committee.

Progenics Pharmaceuticals Relaunches Pivotal Trial of AZEDRA in Pheochromocytoma

Progenics Pharmaceuticals, Inc. announced that it has dosed the first subject in the resumed pivotal Phase 2 clinical study of Azedra in patients with malignant pheochromocytoma and paraganglioma. The trial is being conducted under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). The study is designed to evaluate the efficacy and safety of the administration of two therapeutic doses of Azedra in patients with malignant relapsed/refractory pheochromocytoma or paraganglioma, ultra-orphan cancers with limited treatment options. The primary objective of the study is to determine the clinical benefit of Azedra based on the proportion of study participants with a reduction of all antihypertensive medication by at least 50% for at least six months. The SPA requires that 25% of 58 evaluable patients achieve the primary endpoint. In late 2010, MIP suspended enrollment in the trial to seek additional funding. The trial has now resumed to fulfill enrollment requirements under the SPA. The trial has treated 41 patients and 32% of those patients have achieved the primary endpoint. The most common adverse events observed have been gastroenterological and hematologic disorders.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGNX:US $6.75 USD +0.10

PGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $2.43 USD +0.05
Dynavax Technologies Corp $19.77 USD +0.97
Inovio Pharmaceuticals Inc $7.04 USD -0.13
Peregrine Pharmaceuticals Inc $1.45 USD +0.05
Wyeth Ltd 1,334 INR 0.00
View Industry Companies
 

Industry Analysis

PGNX

Industry Average

Valuation PGNX Industry Range
Price/Earnings 53.5x
Price/Sales 9.5x
Price/Book 3.3x
Price/Cash Flow 52.5x
TEV/Sales 7.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGENICS PHARMACEUTICALS, please visit www.progenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.